2017
DOI: 10.1016/j.colsurfb.2017.05.029
|View full text |Cite
|
Sign up to set email alerts
|

Anti biofilm effect of dihydromyricetin-loaded nanocapsules on urinary catheter infected by Pseudomonas aeruginosa

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
22
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 44 publications
(26 citation statements)
references
References 53 publications
4
22
0
Order By: Relevance
“…Besides, a similar experiment was conducted by Dalcin et al. (), where the retention rates of DMY in nano‐encapsulation were only 55% and 14% after stored at room temperature and at 40 ± 2 °C for 90 days, respectively, which might indicate that the stability of DMY was enhanced remarkably by S‐SEDS compared to the conventional carriers. And the remarkable increase of stability possibly benefit by the secondary encapsulation of L‐SEDS in the Aerosil 300 during the solidification process.…”
Section: Resultssupporting
confidence: 52%
See 1 more Smart Citation
“…Besides, a similar experiment was conducted by Dalcin et al. (), where the retention rates of DMY in nano‐encapsulation were only 55% and 14% after stored at room temperature and at 40 ± 2 °C for 90 days, respectively, which might indicate that the stability of DMY was enhanced remarkably by S‐SEDS compared to the conventional carriers. And the remarkable increase of stability possibly benefit by the secondary encapsulation of L‐SEDS in the Aerosil 300 during the solidification process.…”
Section: Resultssupporting
confidence: 52%
“…Liu, Yin, Wang, and Li () reported that the absolute bioavailability of DMY by oral route was only 4.02% in rats. In order to overcome these limitations, several formulation strategies have been attempted including microemulsion (Solanki, Sarkar, & Dhanwani, ), solid lipid nanoparticles (Gaber, Nafee, & Abdallah, ), cyclodextrin inclusion complexes (Lahianiskiba, Barbot, Bounoure, Joudieh, & Skiba, ), solid dispersion pellets (Ruan, Yu, Fu, & Zhu, ), and nanocapsules (Dalcin et al., ).…”
Section: Introductionmentioning
confidence: 99%
“…3b). Dalcin et al (2017) prepared DMY-loaded nanocapsules by insertion of DMY in polymeric nanoparticles. DMY-loaded nanocapsules not only demonstrated improved physicochemical properties (bioavailability) but also effective antimicrobial and anti-biofilm activity on urinary catheters infected by Pseudomonas aeruginosa.…”
Section: Approaches To Enhance Solubility and Bioavailability Of Dmymentioning
confidence: 99%
“…This is a determinant factor that limited the pharmacological effects and clinical application of DMY. To improve the bioavailability of DMY, researchers have tried to use DMY in new drug delivery systems such as inclusion complexes (Liu, Ma, et al, 2012;Ruan, Yu, Fu, & Zhu, 2005;Yang, Liu, Liu, & Zhang, 2011), nano-encapsule (Dalcin et al, 2017) or microemulsion (Solanki, Sarkar, & Dhanwani, 2012), co-crystals (Wang, Tong, et al, 2016), phospholipid complexes (Liu, Du, Jie, Chen, & Niu., 2009), and acylation (Cao et al, 2017;Guo, Zeng, Lu, & Shu, 2013;Li et al, 2015;Li, Zheng, & Ning., 2005) to provide higher solubility and bioavailability. In addition, the pharmacokinetic characteristics of DMY in animal models and human body are also vital to the evaluation of their in vivo bioavailability efficacy.…”
Section: Introductionmentioning
confidence: 99%
“…The MBC results are shown in The action of the EO was faster as compared to N-EO, which can be associated with the gradual release of EO from the nanocapsules (Dalcin et al, 2017), suggesting a controlled release of antimicrobial compounds. In bacteria treated with N-B (bare nanoparticles), no significant differences were observed in the growth of B. cereus and L. monocytogenes in comparison to the control group.…”
Section: Antibacterial Assaysmentioning
confidence: 94%